Three Pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Valeant Pharmaceuticals (NYSE:VRX) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Biovail Corporation International develops and distributes drugs. In Portfolio Grader’s specific subcategory of Sales Growth, VRX also gets an A. For more information, get Portfolio Grader’s complete analysis of VRX stock.
Bristol-Myers Squibb (NYSE:BMY) improves from a C to a B rating this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. The stock price has risen 7.2% over the past month, better than the 3.3% increase the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BMY stock.
This week, Watson Pharmaceuticals (NYSE:WPI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.